Stock listing
BSE:LAURUSLABS Laurus Labs Ltd. Share Price
Indian listing (BSE) of Laurus Labs Ltd. · home listing NSE:LAURUSLABS
Follow Laurus Labs Ltd. into a list and get an email when it puts out news.
Home listing price · NSE:LAURUSLABS
₹2,294.60 INR -27.90 (-1.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NSE:LAURUSLABS
- Day range
- ₹2,286.80 – ₹2,320.00 INRNov 20, 2026
- Volume
- 878,794 sharesNov 20, 2026
- Market cap
- ₹1.24T INRAt the close on Nov 20, 2026 · price × 540.3M shares outstanding
- 52-week range
- ₹917.95 – ₹2,488.00 INRLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₹5.37B INRMedian day 1.63M shares · 3 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NSE:LAURUSLABS · Home | ₹2,294.60 INR | -27.90 (-1.2%) | 878,794 | ₹2,294.10 | ₹2,320.00 | ₹2,286.80 | ₹2,322.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NSE:LAURUSLABS · INR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₹2,294.60 | -27.90 | -1.2% | ₹2,294.10 | ₹2,320.00 | ₹2,286.80 | 878,794 | |
| ₹2,322.50 | -15.50 | -0.7% | ₹2,345.00 | ₹2,362.60 | ₹2,317.00 | 1,611,891 | |
| ₹2,338.00 | +118.00 | +5.3% | ₹2,220.00 | ₹2,348.80 | ₹2,214.80 | 4,887,888 | |
| ₹2,220.00 | -204.00 | -8.4% | ₹2,430.00 | ₹2,439.00 | ₹2,190.00 | 6,836,877 | |
| ₹2,424.00 | +24.00 | +1.0% | ₹2,400.00 | ₹2,446.90 | ₹2,394.00 | 2,277,547 | |
| ₹2,400.00 | -29.00 | -1.2% | ₹2,427.00 | ₹2,434.20 | ₹2,380.00 | 1,764,909 | |
| ₹2,429.00 | -25.00 | -1.0% | ₹2,480.00 | ₹2,488.00 | ₹2,416.90 | 4,133,906 | |
| ₹2,454.00 | +114.00 | +4.9% | ₹2,351.50 | ₹2,480.00 | ₹2,351.50 | 4,026,300 | |
| ₹2,340.00 | -6.00 | -0.3% | ₹2,329.70 | ₹2,341.50 | ₹2,309.10 | 1,445,360 | |
| ₹2,346.00 | +22.20 | +1.0% | ₹2,328.30 | ₹2,346.00 | ₹2,288.20 | 1,448,875 | |
| ₹2,323.80 | +0.80 | 0.0% | ₹2,291.00 | ₹2,343.90 | ₹2,285.60 | 3,218,928 | |
| ₹2,323.00 | -25.00 | -1.1% | ₹2,350.10 | ₹2,354.90 | ₹2,252.40 | 4,025,877 | |
| ₹2,348.00 | -57.50 | -2.4% | ₹2,406.00 | ₹2,441.90 | ₹2,347.00 | 3,047,198 | |
| ₹2,405.50 | +161.50 | +7.2% | ₹2,246.60 | ₹2,405.50 | ₹2,206.10 | 7,909,825 | |
| ₹2,244.00 | +62.10 | +2.8% | ₹2,190.00 | ₹2,244.00 | ₹2,166.00 | 2,898,447 | |
| ₹2,181.90 | +39.90 | +1.9% | ₹2,142.00 | ₹2,198.80 | ₹2,131.70 | 2,200,547 | |
| ₹2,142.00 | +83.10 | +4.0% | ₹2,075.00 | ₹2,143.10 | ₹2,067.40 | 3,116,290 | |
| ₹2,058.90 | +88.90 | +4.5% | ₹1,960.00 | ₹2,058.90 | ₹1,951.60 | 1,858,038 | |
| ₹1,970.00 | -32.50 | -1.6% | ₹1,987.50 | ₹2,009.60 | ₹1,933.50 | 1,893,589 | |
| ₹2,002.50 | -10.00 | -0.5% | ₹1,993.50 | ₹2,019.80 | ₹1,956.60 | 1,538,717 | |
| ₹2,012.50 | -56.50 | -2.7% | ₹2,052.90 | ₹2,079.80 | ₹1,993.40 | 1,275,844 | |
| ₹2,069.00 | +8.90 | +0.4% | ₹2,060.10 | ₹2,089.00 | ₹2,052.20 | 1,133,053 | |
| ₹2,060.10 | +41.60 | +2.1% | ₹2,030.40 | ₹2,086.00 | ₹2,028.70 | 1,606,547 | |
| ₹2,018.50 | -18.40 | -0.9% | ₹2,025.00 | ₹2,046.30 | ₹2,008.00 | 858,713 | |
| ₹2,036.90 | -22.50 | -1.1% | ₹2,049.00 | ₹2,057.30 | ₹2,019.20 | 1,301,046 | |
| ₹2,059.40 | -9.80 | -0.5% | ₹2,047.10 | ₹2,065.00 | ₹2,007.80 | 1,141,354 | |
| ₹2,069.20 | +32.60 | +1.6% | ₹2,044.10 | ₹2,069.20 | ₹2,036.10 | 1,417,097 | |
| ₹2,036.60 | +38.70 | +1.9% | ₹1,997.90 | ₹2,048.00 | ₹1,988.90 | 1,358,268 | |
| ₹1,997.90 | -54.90 | -2.7% | ₹2,055.00 | ₹2,055.00 | ₹1,997.90 | 1,394,208 | |
| ₹2,052.80 | +2.80 | +0.1% | ₹2,052.00 | ₹2,065.20 | ₹2,035.60 | 1,499,990 | |
| ₹2,050.00 | +78.60 | +4.0% | ₹1,968.90 | ₹2,054.90 | ₹1,958.00 | 2,197,316 | |
| ₹1,971.40 | -12.60 | -0.6% | ₹1,994.00 | ₹2,002.00 | ₹1,955.10 | 1,374,138 | |
| ₹1,984.00 | 0.00 | 0.0% | ₹1,984.00 | ₹1,984.00 | ₹1,984.00 | 0 | |
| ₹1,984.00 | +4.00 | +0.2% | ₹1,973.60 | ₹2,006.90 | ₹1,952.10 | 1,459,687 | |
| ₹1,980.00 | +1.00 | +0.1% | ₹1,993.00 | ₹2,001.60 | ₹1,955.10 | 1,397,926 | |
| ₹1,979.00 | -31.70 | -1.6% | ₹2,020.70 | ₹2,024.90 | ₹1,979.00 | 2,431,575 | |
| ₹2,010.70 | +3.70 | +0.2% | ₹2,000.00 | ₹2,012.30 | ₹1,984.80 | 950,451 | |
| ₹2,007.00 | -19.20 | -0.9% | ₹2,026.00 | ₹2,040.00 | ₹1,979.20 | 1,442,142 | |
| ₹2,026.20 | -7.80 | -0.4% | ₹2,021.10 | ₹2,055.30 | ₹2,020.00 | 1,388,039 | |
| ₹2,034.00 | +27.50 | +1.4% | ₹2,009.50 | ₹2,037.20 | ₹1,999.70 | 1,363,988 | |
| ₹2,006.50 | -11.00 | -0.5% | ₹2,018.00 | ₹2,032.80 | ₹2,002.20 | 1,487,044 | |
| ₹2,017.50 | +63.50 | +3.2% | ₹1,966.60 | ₹2,023.50 | ₹1,963.80 | 2,170,267 | |
| ₹1,954.00 | +5.90 | +0.3% | ₹1,962.00 | ₹1,982.00 | ₹1,954.00 | 2,655,873 | |
| ₹1,948.10 | +42.60 | +2.2% | ₹1,898.00 | ₹1,964.50 | ₹1,894.80 | 1,645,108 | |
| ₹1,905.50 | -21.40 | -1.1% | ₹1,924.60 | ₹1,940.40 | ₹1,863.50 | 2,871,410 | |
| ₹1,926.90 | -42.10 | -2.1% | ₹1,975.00 | ₹1,981.00 | ₹1,915.60 | 1,538,262 | |
| ₹1,969.00 | 0.00 | 0.0% | ₹1,969.00 | ₹1,969.00 | ₹1,969.00 | 0 | |
| ₹1,969.00 | +24.00 | +1.2% | ₹1,943.00 | ₹1,981.80 | ₹1,918.10 | 2,277,375 | |
| ₹1,945.00 | +8.00 | +0.4% | ₹1,932.60 | ₹1,950.50 | ₹1,920.90 | 1,067,622 | |
| ₹1,937.00 | -9.90 | -0.5% | ₹1,946.90 | ₹1,955.00 | ₹1,917.90 | 1,822,218 | |
| ₹1,946.90 | +106.90 | +5.8% | ₹1,870.80 | ₹1,952.00 | ₹1,862.70 | 2,115,447 | |
| ₹1,840.00 | 0.00 | 0.0% | ₹1,840.00 | ₹1,840.00 | ₹1,840.00 | 0 | |
| ₹1,840.00 | -28.50 | -1.5% | ₹1,855.00 | ₹1,871.80 | ₹1,835.20 | 1,075,943 | |
| ₹1,868.50 | +4.50 | +0.2% | ₹1,864.90 | ₹1,876.60 | ₹1,852.60 | 1,506,361 | |
| ₹1,864.00 | +2.40 | +0.1% | ₹1,853.20 | ₹1,864.40 | ₹1,811.70 | 2,265,630 | |
| ₹1,861.60 | -53.40 | -2.8% | ₹1,888.90 | ₹1,895.00 | ₹1,837.40 | 3,530,385 | |
| ₹1,915.00 | -23.50 | -1.2% | ₹1,945.00 | ₹1,949.00 | ₹1,847.80 | 30,995,343 | |
| ₹1,938.50 | +9.10 | +0.5% | ₹1,929.70 | ₹1,938.50 | ₹1,910.10 | 2,231,476 | |
| ₹1,929.40 | +42.40 | +2.2% | ₹1,891.30 | ₹1,930.00 | ₹1,878.40 | 4,249,869 | |
| ₹1,887.00 | +20.80 | +1.1% | ₹1,871.10 | ₹1,898.30 | ₹1,857.40 | 3,334,188 | |
| ₹1,866.20 | +65.20 | +3.6% | ₹1,808.00 | ₹1,869.40 | ₹1,796.50 | 3,550,945 | |
| ₹1,801.00 | -1.00 | -0.1% | ₹1,800.00 | ₹1,810.80 | ₹1,790.00 | 2,894,242 | |
| ₹1,802.00 | -23.00 | -1.3% | ₹1,825.00 | ₹1,836.40 | ₹1,790.30 | 1,401,995 | |
| ₹1,825.00 | +23.20 | +1.3% | ₹1,819.00 | ₹1,832.00 | ₹1,813.80 | 1,315,065 |
Splits
1 split · NSE:LAURUSLABS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 5-for-1 | Split |
- Ticker
- BSE:LAURUSLABS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- BSE
- Currency
- INR
What changed lately
Latest news release · Oct 29, 2026
Laurus Labs Limited has informed the Exchange regarding a press release dated October 29, 2026, titled "Press Release on the Financial Results for the quarter and half-year ended September 30, 2026 along with the acquisition of Galenvs Sciences.".
Latest earnings call · Oct 29, 2026
Laurus Labs (NSE:LAURUSLABS) Q2 2027 Earnings Call
Replay and transcript
Latest deck · Oct 29, 2026
Q2 FY2027 Earnings Presentation
Earnings · 26 slides
Latest news
Laurus Labs Limited has informed the Exchange regarding a press release dated October 29, 2026, titled "Press Release on the Financial Results for the quarter and half-year ended September 30, 2026 along with the acquisition of Galenvs Sciences.".
Oct 29, 2026
Closed ₹2,244.00 (+2.8%) on Oct 29, 2026
Laurus Labs Ltd. Press Release Jul 24 2026
Jul 24, 2026
Closed ₹1,601.20 (+2.1%) on Jul 24, 2026
Press Release Apr 30 2026
Apr 30, 2026
Closed ₹1,100.95 (-0.5%) on Apr 30, 2026
Press Release Jan 23 2026
Jan 23, 2026
Closed ₹1,016.40 (0.0%) on Jan 26, 2026
Laurus Labs Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 4 in the last 12 months · 40 in all · newest Oct 29, 2026 · oldest 2020
- Calls
- 2 calls with a replay · 2 with a transcript · latest Oct 29, 2026
- Decks
- 43 decks · latest Oct 29, 2026
Where Laurus Labs Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NSE:LAURUSLABS · Home listing | NSE | India | INR |
| BSE:LAURUSLABS · This page | BSE | India | INR |
Valuation
P/E 92.5× against a median of 39.5×: the highest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₹1.27T INR
- P/E
- 92.5×
- EV/sales
- 16.2×
- EV/EBITDA
- 53.2×
- Price/book
- 20.5×
- Gross margin
- 48.0%
- Operating margin
- 24.1%
- Net margin
- 17.1%
- Debt to equity
- 0.4×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Laurus Labs Ltd. · NSE:LAURUSLABS | US$13.38B | US$13.66B | 92.5× | 16.2× | 53.2× | 20.5× | 17.1% | 0.4× | n/a |
| Yunnan Baiyao Group Co. Ltd. Class A · SZSE:000538 | US$15.07B | US$13.10B | 19.4× | 2.0× | n/a | 2.5× | 12.2% | 0.0× | n/a |
| Jazz Pharmaceuticals plc · NASDAQ:JAZZ | US$14.95B | US$18.48B | 72.6× | 3.9× | n/a | 3.6× | 4.4% | 1.3× | 0.64 |
| Ipsen SA · EURONEXT:IPN | US$14.62B | US$13.51B | 30.0× | 3.4× | 11.2× | 2.8× | 12.1% | 0.2× | n/a |
| Zydus Lifesciences Limited · NSE:ZYDUSLIFE | US$12.92B | US$13.86B | 28.6× | 4.2× | 17.9× | 4.3× | 13.8% | 0.5× | n/a |
| Elanco Animal Health Incorporated · NYSE:ELAN | US$12.87B | US$15.85B | n/a | 3.1× | 13.1× | 1.9× | −2.9% | 0.5× | 1.20 |
| Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY | US$12.50B | US$12.45B | 41.4× | 3.5× | 22.6× | 3.0× | 8.5% | 0.2× | n/a |
| Cipla Ltd · NSE:CIPLA | US$12.34B | US$11.26B | 39.5× | 3.7× | 21.6× | 3.2× | 10.4% | 0.0× | n/a |
| Mankind Pharma Ltd. · NSE:MANKIND | US$11.88B | US$12.18B | 49.1× | 7.3× | 27.7× | 6.3× | 14.6% | 0.3× | n/a |
| Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A · SSE:600436 | US$11.62B | US$11.29B | 58.9× | 9.5× | n/a | 5.5× | 16.7% | 0.0× | n/a |
| Aurobindo Pharma Ltd · NSE:AUROPHARMA | US$11.17B | US$11.02B | 25.9× | 2.8× | 13.4× | 2.6× | 10.8% | 0.2× | n/a |
| Median of the others | US$12.68B | US$12.78B | 39.5× | 3.6× | 17.9× | 3.1× | 11.5% | 0.2× | 0.92 |
Forecasts
Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 2156.29 INR · Analysts' mean
- EPS, year to Mar 2027
- 30.05 · 13 analysts
- Revenue, year to Mar 2027
- 86.49B · 15 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Satyanarayana Chava | Executive Director and Chief Executive Officer |
| Ch. Sita Ramaiah | Executive Vice President - Finance |
| V. V. Ravi Kumar | Executive Director and Chief Financial Officer |
| Srinivasa Rao S | President - Manufacturing and Operations |
| Suresh Poda | President - Advanced biologics |
| Thomas Versosky | President - FDF, North America |
| V Uma Maheswer Rao | President - Chemical R&D |
| Arnaud Martin | EVP & Head Business Development - CDMO |
| Ch. Venkata Ramana Rao | Executive Vice President - Intellectual Property Management |
| Jyothi Basu Abbineni | Executive Vice President - Chemical R&D |
| Martyn Oliver James Peck | Executive Vice President - Business Development |
| Narasimha Rao Chava | Executive Vice President - Human Resources |
| Narasimha Rao DVL | Executive Vice President - Synthesis |
| Rajaram Iyer | Executive Vice President - Portfolio Management |
| S. Srinivas Rao | Executive Vice President - Manufacturing |
| Sumeet Sobti | Senior Vice President - Supply Chain Management |
| C. V. Lakshmana Rao | Executive Director – Quality |
| Krishna Chaitanya Chava | Executive Director - CDMO Small Molecules |
| Soumya Chava | Executive Director - Affordable Medicines |
Board
| Director | Role |
|---|---|
| Ravindranath Kancherla | Non-Executive Independent Director and Chairman of the Board |
| Aruna Bhinge | Non-Executive Independent Director |
| C. V. Lakshmana Rao | Executive Director – Quality |
| Karnam Sekar | Non-Executive Independent Director |
| Krishna Chaitanya Chava | Executive Director - CDMO Small Molecules |
| Ramesh Subrahmanian | Non-Executive Independent Director |
| Satyanarayana Chava | Executive Director and Chief Executive Officer |
| Sekar Karnam | Non-Executive Independent Director |
| Shekhar C. Mande | Non-Executive Independent Director |
| Soumya Chava | Executive Director - Affordable Medicines |
| Sutapa Banerjee | Non-Executive Independent Director |
| V. V. Ravi Kumar | Executive Director and Chief Financial Officer |
Events
- Next results
- Jan 22, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Laurus Labs (NSE:LAURUSLABS) Q2 2027 Earnings Call | Thu, Oct 29, 2026 · 11:33 AM ET | Replay |
| Laurus Labs (NSE:LAURUSLABS) Q1 2027 Earnings Call | Fri, Jul 24, 2026 · 1:32 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2027 | Oct 29, 2026 · Before open | +2.9% |
| Q1 2027 | Jul 24, 2026 · Before open | +2.1% |
| Q4 2026 | Apr 30, 2026 · Before open | −0.5% |
| Q3 2026 | Jan 23, 2026 · Before open | +1.1% |
| Q2 2026 | Oct 23, 2025 · Before open | +1.1% |
| Q1 2026 | Jul 25, 2025 · Before open | +0.1% |
| Q4 2025 | Apr 24, 2025 · Before open | −0.8% |
| Q3 2025 | Jan 24, 2025 · Before open | +3.0% |
| Q2 2025 | Oct 24, 2024 · Before open | −0.5% |
| Q1 2025 | Jul 25, 2024 · Before open | −0.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | Apr 25, 2024 · Before open | −2.0% |
| Q3 2024 | Jan 24, 2024 · Before open | +0.5% |
| Q2 2024 | Oct 20, 2023 · Before open | +1.1% |
| Q1 2024 | Jul 27, 2023 · Before open | +0.8% |
| Q4 2023 | Apr 27, 2023 · Before open | −2.6% |
| Q3 2023 | Jan 30, 2023 · Before open | −0.0% |
| Q2 2023 | Oct 21, 2022 · Before open | −7.6% |
| Q1 2023 | Jul 27, 2022 · Before open | +6.1% |
| Q4 2022 | Apr 28, 2022 · Before open | −1.3% |
| Q3 2022 | Jan 27, 2022 · Before open | −2.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 FY2027 Earnings Presentation | Earnings | 26 slides | Oct 29, 2026 |
| Investor Presentation (September 2026) | Investor deck | 22 slides | Sep 18, 2026 |
| Q1 FY2027 Earnings Presentation | Earnings | 21 slides | Jul 24, 2026 |
| FY2026 Earnings Presentation | Earnings | 30 slides | Apr 30, 2026 |
| Q3 FY2026 Earnings Presentation | Earnings | 26 slides | Jan 23, 2026 |
| Q2 FY2026 Earnings Presentation | Earnings | 28 slides | Oct 23, 2025 |
| Investor Presentation (September 2025) | Investor deck | 24 slides | Sep 12, 2025 |
| Q1 FY2026 Earnings Presentation | Earnings | 24 slides | Jul 25, 2025 |
| FY2025 Earnings Presentation | Earnings | 36 slides | Apr 24, 2025 |
| Q3 FY2025 Earnings Presentation | Earnings | 31 slides | Jan 24, 2025 |
All 43 decks
Financials
Annual, in INR
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68.1B | 55.5B | 50.4B | 60.4B | 49.4B | 48.1B | 28.3B | 22.9B | 20.6B | 19.0B |
| Cost of revenue | 40.7B | 25.9B | 25.4B | 28.6B | 22.5B | 22.0B | 14.5B | 12.6B | 10.8B | 10.1B |
| Gross profit | 27.4B | 29.7B | 25.0B | 31.8B | 26.9B | 26.1B | 13.9B | 10.3B | 9.72B | 8.91B |
| Research and development | 276.6M | 553.0M | 437.6M | 255.9M | 294.7M | 172.9M | 151.8M | 131.5M | 134.5M | 119.2M |
| Selling, general and administrative | 2.43B | 7.23B | 6.42B | 5.83B | 5.04B | 4.36B | 3.49B | 2.98B | 2.65B | 2.30B |
| Operating income | 13.0B | 21.7B | 18.0B | 25.6B | 21.5B | 21.6B | 10.2B | 7.11B | 7.02B | 6.56B |
| Depreciation and amortization | 4.80B | 4.30B | 3.85B | 3.24B | 2.51B | 2.05B | 1.87B | 1.64B | 1.25B | 1.06B |
| EBITDA | 17.8B | 26.0B | 21.9B | 28.8B | 24.0B | 23.6B | 12.0B | 8.75B | 8.28B | 7.62B |
| Interest expense | 1.71B | 2.13B | 1.80B | 1.43B | 919.6M | 663.8M | 786.0M | 766.6M | 729.3M | 969.9M |
| Income before tax | 11.8B | 4.88B | 2.30B | 11.1B | 10.8B | 13.0B | 2.94B | 1.20B | 2.37B | 2.34B |
| Income tax | 2.92B | 1.30B | 681.5M | 3.12B | 2.51B | 3.17B | 383.4M | 259.9M | 698.1M | 438.6M |
| Net income | 8.89B | 3.58B | 1.61B | 7.90B | 8.28B | 9.84B | 2.55B | 937.6M | 1.68B | 1.90B |
| Earnings per share, basic | 16.45 | 6.64 | 2.97 | 14.64 | 15.35 | 18.28 | 4.79 | 1.76 | 3.15 | 4.18 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.14B | 995.4M | 1.39B | 456.7M | 753.5M | 484.6M | 16.9M | 29.7M | 30.0M | 24.2M |
| Short-term investments | 443.9M | 24.2M | 27.9M | 5.90M | 390.7M | 880.0K | 270.0K | -668.3M | -651.2M | |
| Receivables | 21.6B | 20.4B | 17.0B | 16.3B | 13.9B | 13.6B | 8.52B | 7.42B | 6.02B | 6.02B |
| Inventory | 23.4B | 19.4B | 18.5B | 16.8B | 17.6B | 15.8B | 9.05B | 6.82B | 5.85B | 5.09B |
| Current assets | 48.3B | 43.3B | 38.3B | 34.6B | 33.4B | 30.7B | 18.1B | 14.6B | 12.5B | 11.4B |
| Property, plant and equipment | 43.2B | 40.5B | 37.0B | 32.1B | 22.8B | 17.7B | 17.2B | 16.3B | 13.6B | |
| Goodwill | 2.46B | 2.46B | 2.46B | 2.46B | 2.46B | 2.46B | 97.4M | 97.4M | 97.4M | 97.4M |
| Total assets | 105.1B | 93.4B | 83.9B | 76.6B | 69.7B | 57.5B | 37.5B | 33.3B | 30.2B | 26.5B |
| Accounts payable | 12.5B | 9.58B | 10.5B | 7.11B | 8.76B | 11.8B | 6.16B | 4.88B | 3.12B | 2.63B |
| Current liabilities | 36.4B | 35.4B | 31.1B | 24.3B | 26.8B | 24.6B | 16.9B | 14.2B | 13.1B | 11.3B |
| Long-term debt | 6.11B | 6.46B | 7.98B | 7.61B | 5.96B | 4.29B | 1.64B | 2.57B | 1.38B | 1.19B |
| Total debt | 25.2B | 27.6B | 25.8B | 20.2B | 17.8B | 14.8B | 10.8B | 10.4B | 9.80B | 8.42B |
| Total liabilities | 50.8B | 47.3B | 42.7B | 36.1B | 36.1B | 31.5B | 19.8B | 17.7B | 15.3B | 13.2B |
| Shareholders' equity | 53.0B | 44.7B | 41.1B | 40.4B | 33.5B | 26.0B | 17.7B | 15.6B | 14.8B | 13.3B |
| Shares outstanding | 540.3M | 539.6M | 539.7M | 539.6M | 539.2M | 538.1M | 533.5M | 532.6M | 531.7M | 455.2M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 14.6B | 6.02B | 6.66B | 9.94B | 9.11B | 7.33B | 3.47B | 2.98B | 3.42B | 3.32B |
| Capital spending | -10.7B | -6.41B | -6.78B | -9.90B | -8.77B | -6.89B | -2.22B | -2.54B | -3.91B | -2.77B |
| Free cash flow | 3.89B | -393.5M | -126.2M | 37.4M | 342.6M | 442.3M | 1.25B | 434.0M | -486.2M | 544.9M |
| Cash from investing | -11.0B | -6.82B | -8.22B | -9.96B | -9.14B | -9.41B | -2.21B | -2.53B | -3.84B | -2.89B |
| Cash from financing | -3.54B | 392.8M | 2.50B | -266.4M | 302.6M | 2.55B | -1.28B | -447.7M | 422.4M | -536.1M |
| Dividends paid | -863.3M | -431.3M | -861.8M | -1.07B | -858.6M | -750.4M | -320.0M | -159.0M | -158.6M | -49.3M |
| Share buybacks | 101.7M | 25.6M | 2.39B | 1.63B | 883.5M | 73.7M | 538.3M | 1.68B | 1.05B | |
| Change in cash | 138.8M | -394.0M | 932.7M | -296.8M | 268.9M | 467.7M | -12.8M | -360.0K | 5.81M | -103.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Laurus Labs Limited has informed the Exchange regarding a press release dated October 29, 2026, titled "Press Release on the Financial Results for the quarter and half-year ended September 30, 2026 along with the acquisition of Galenvs Sciences.". | Oct 29, 2026 | Results | NSE India |
| Laurus Labs Ltd. Press Release Jul 24 2026 | Jul 24, 2026 | Results | NSE India |
| Press Release Apr 30 2026 | Apr 30, 2026 | Results | NSE India |
| Press Release Jan 23 2026 | Jan 23, 2026 | Results | NSE India |
| Press Release Oct 23 2025 | Oct 23, 2025 | Results | NSE India |
| Press Release Jul 25 2025 | Jul 25, 2025 | Results | NSE India |
| Press Release Apr 24 2025 | Apr 24, 2025 | Results | NSE India |
| Press Release Jan 24 2025 | Jan 24, 2025 | Other filings | NSE India |
| Press Release Dec 06 2024 | Dec 6, 2024 | Other filings | NSE India |
| Press Release Oct 24 2024 | Oct 24, 2024 | Results | NSE India |
All 39 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Press Release Sep 16 2024 | Sep 16, 2024 | Operations update | NSE India |
| Press Release Sep 13 2024 | Sep 13, 2024 | Operations update | NSE India |
| Press Release Jul 25 2024 | Jul 25, 2024 | Other filings | NSE India |
| Press Release Apr 25 2024 | Apr 25, 2024 | Other filings | NSE India |
| Press Release Jan 25 2024 | Jan 25, 2024 | Other filings | NSE India |
| Press Release Jan 24 2024 | Jan 24, 2024 | Results | NSE India |
| Press Release Oct 20 2023 | Oct 20, 2023 | Other filings | NSE India |
| Press Release Jul 27 2023 | Jul 27, 2023 | Results | NSE India |
| Press Release Jun 19 2023 | Jun 19, 2023 | Operations update | NSE India |
| Press Release May 31 2023 | May 31, 2023 | Other filings | NSE India |
| Press Release May 02 2023 | May 2, 2023 | Operations update | NSE India |
| Press Release Apr 27 2023 | Apr 27, 2023 | Results | NSE India |
| Press Release Jan 30 2023 | Jan 30, 2023 | Results | NSE India |
| Press Release Oct 21 2022 | Oct 21, 2022 | Results | NSE India |
| Press Release Jul 27 2022 | Jul 27, 2022 | Results | NSE India |
| Press Release Apr 28 2022 | Apr 28, 2022 | Results | NSE India |
| Press Release Jan 27 2022 | Jan 27, 2022 | Other filings | NSE India |
| Press Release Jan 21 2022 | Jan 21, 2022 | Other filings | NSE India |
| Press Release Nov 19 2021 | Nov 19, 2021 | Acquisition or disposal | NSE India |
| Press Release Oct 28 2021 | Oct 28, 2021 | Other filings | NSE India |
| Press Release Sep 14 2021 | Sep 14, 2021 | Operations update | NSE India |
| Press Release Jul 29 2021 | Jul 29, 2021 | Results | NSE India |
| Press Release Jul 02 2021 | Jul 2, 2021 | Other filings | NSE India |
| Press Release Apr 29 2021 | Apr 29, 2021 | Results | NSE India |
| Press Release Mar 04 2021 | Mar 4, 2021 | Ownership change notice | NSE India |
| Press Release Feb 10 2021 | Feb 10, 2021 | Other filings | NSE India |
| Press Release Jan 28 2021 | Jan 28, 2021 | Results | NSE India |
| Press Release Nov 25 2020 | Nov 25, 2020 | Acquisition or disposal | NSE India |
| Press Release Oct 29 2020 | Oct 29, 2020 | Results | NSE India |
Cap table
Built by 6ix from Laurus Labs Ltd.’s releases
- Common shares
- 540,312,218
- Fully diluted
- 540,312,218
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 540,312,218 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 540,312,218 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Arnaud Martin | EVP & Head Business Development - CDMO · Since at least Nov 4, 2026 |
| Aruna Bhinge | Non-Executive Independent Director · Since at least Nov 6, 2026 |
| Ch. Sita Ramaiah | Executive Vice President - Finance · Since at least Nov 4, 2026 |
| Ch. Venkata Ramana Rao | Executive Vice President - Intellectual Property Management · Since at least Nov 4, 2026 |
| Jyothi Basu Abbineni | Executive Vice President - Chemical R&D · Since at least Nov 4, 2026 |
| Karnam Sekar | Non-Executive Independent Director · Since at least Nov 4, 2026 |
| Krishna Chaitanya Chava | Executive Director - CDMO Small Molecules · Since at least Nov 6, 2026 |
| Lakshmana Rao C V | Executive Director – Quality · Since at least Nov 6, 2026 |
| Martyn Oliver James Peck | Executive Vice President - Business Development · Since at least Nov 4, 2026 |
| Narasimha Rao Chava | Executive Vice President - Human Resources · Since at least Nov 4, 2026 |
All 26 people
| Person | Seat |
|---|---|
| Narasimha Rao DVL | Executive Vice President - Synthesis · Since at least Nov 4, 2026 |
| Rajaram Iyer | Executive Vice President - Portfolio Management · Since at least Nov 4, 2026 |
| Ramesh Subrahmanian | Non-Executive Independent Director · Since at least Nov 6, 2026 |
| Ravindranath Kancherla | Non-Executive Independent Director and Chairman of the Board · Since at least Nov 6, 2026 |
| Satyanarayana Chava | Executive Director and Chief Executive Officer · Since at least Oct 8, 2025 |
| Sekar Karnam | Non-Executive Independent Director · Since at least Nov 6, 2026 |
| Shekhar C. Mande | Non-Executive Independent Director · Since at least Nov 6, 2026 |
| Soumya Chava | Executive Director - Affordable Medicines · Since at least Nov 6, 2026 |
| Srinivasa Rao S | President - Manufacturing and Operations · Since at least Nov 4, 2026 |
| S. Srinivas Rao | Executive Vice President - Manufacturing · Since at least Nov 4, 2026 |
| Sumeet Sobti | Senior Vice President - Supply Chain Management · Since at least Nov 4, 2026 |
| Suresh Poda | President - Advanced biologics · Since at least Nov 4, 2026 |
| Sutapa Banerjee | Non-Executive Independent Director · Since at least Nov 6, 2026 |
| Thomas Versosky | President - FDF, North America · Since at least Nov 4, 2026 |
| V Uma Maheswer Rao | President - Chemical R&D · Since at least Nov 4, 2026 |
| V. V. Ravi Kumar | Executive Director and Chief Financial Officer · Since at least Nov 6, 2026 |
Log in to ask 6ix AI your own questions about Laurus Labs Ltd.